The avidity of PR3‐ANCA in patients with granulomatosis with polyangiitis during follow‐up. (23rd May 2016)

• Record Type: Journal Article
• Authors: Kemna, M. J.; Schlumberger, W.; van Paassen, P.; Dähnrich, C.; Damoiseaux, J. G. M. C.; Cohen Tervaert, J. W.
• Is Part Of: Clinical and experimental immunology. Volume 185:Number 2(2016:Aug.)
• Page Start: 141
• Page End: 147
• Publication Date: 2016-05-23
• Subjects: ANCA‐associated vasculitis -- avidity -- follow‐up -- relapse -- granulomatosis with polyangiitis -- PR3‐ANCA -- proteinase 3 -- relative avidity index; Immunopathology -- Periodicals; 616.079
• DOI: 10.1111/cei.12796
• Languages: English
• ISSNs: 0009-9104

Abstract

Summary: The objective of this study is to investigate whether the avidity of proteinase‐3‐anti‐neutrophil cytoplasmic antibody (PR3‐ANCA) changes during follow‐up in different subgroups of patients with granulomatosis with polyangiitis (GPA). We selected 10 patients with renal relapsing GPA, 10 patients with renal non‐relapsing GPA and 10 patients with non‐renal relapsing GPA. In all patients, an ANCA rise occurred during remission. The avidity was measured using a chaotropic approach at the time of an ANCA rise and at the time of a relapse in relapsing patients or time‐matched during remission in non‐relapsing patients. No difference was observed in the avidity at the ANCA rise between renal relapsing patients [26·2% (15·5–47·5)], renal patients without a relapse [39·6% (21·2–63·4)] and non‐renal relapsing patients [34·2% (21·6–59·5)]. In renal relapsing patients, the avidity increased significantly from the moment of the ANCA rise to the relapse [difference 6·4% (0·0–17·1), P = 0·0273]. The avidity did not increase after an ANCA rise in renal non‐relapsing patients [difference 3·5 (−6·0 to 10·1), P = 0·6250] or in non‐renal relapsing patients [difference −3·1% (−8·0 to 5·0), P = 0·5703]. The avidity of PR3‐ANCA increases after an ANCA rise during follow‐up in renal relapsing patients, but not after an ANCA rise in renal patients who remain in remission or in non‐renal relapsing patients.